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Patients with cancer who develop venous thromboembolism (VTE) are at elevated risk for recurrent thrombotic events, even during
anticoagulant therapy. The clinical picture is further complicated because these patients are also at increased risk of bleeding while on
anticoagulants. In general, there are four key goals of treatment for VTE: preventing fatal pulmonary embolism (PE); reducing short-
term morbidities associated with acute leg or lung thrombus; preventing recurrent VTE; and preventing the long-term sequelae of
VTE (e.g., post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension). A fifth goal – minimising the risk for
bleeding while on anticoagulation – is particularly warranted in patients with cancer. Traditionally, pharmacological treatment of VTE
has two phases, with the transition between phases marked by a switch from a rapid-acting, parenterally administered anticoagulant
(such as unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), or fondaparinux) to an oral vitamin K antagonist
(e.g., warfarin). Recent clinical trials of established agents and the advent of new pharmacological options are changing this paradigm.
Low-molecular-weight heparin continued for 6 months is more effective than warfarin in the secondary prevention of VTE in cancer
patients without increasing the risk of bleeding and is now the preferred treatment option. Given the impact of VTE on short-term
and long-term outcomes in patients with cancer, a group of health-care providers based in the United Kingdom gathered in London
in 2009 to discuss recent data on cancer-associated thrombosis and to evaluate how these recommendations can be integrated or
translated into UK clinical practice. This article, which is the third of four articles covering key topics in cancer thrombosis, focuses on
treatment and secondary prevention of VTE in cancer patients.
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It has been clearly established that patients with cancer have an
increased risk of venous thromboembolism (VTE) compared with
patients without cancer. Venous thromboembolism, comprising
deep vein thrombosis (DVT) and pulmonary embolism (PE), is an
important cause of morbidity and mortality in cancer patients and
its treatment is particularly difficult because standard therapy
is less effective in preventing recurrences and causes more
bleeding than is the case in non-cancer patients with VTE. The
need to perform surgery or invasive procedures in patients with
cancer receiving anticoagulants, as well as the frequent presence
of thrombocytopenia due to chemotherapy or haematological
malignancy, widespread use of in-dwelling central lines, adminis-
tration of multiple interacting drugs, and varying dietary intake
during the course of cancer therapy, all add to the particular
challenges faced in VTE treatment.
Randomised clinical trials over the past decade have substan-
tially altered the management of VTE in patients with cancer,
leading to improved outcomes and quality of life. Unfractionated
heparin (UFH) and vitamin K antagonists (e.g., warfarin) have
been the mainstay of management of VTE since the mid-twentieth
century, followed by the widespread replacement of UFH by
low-molecular-weight heparins (LMWH) since the 1990s. The
appearance of new classes of oral anticoagulants that directly
inhibit specific clotting factor targets, such as thrombin and factor
Xa, may further transform the management of VTE in patients
with cancer in the years to come.
Venous thromboembolism is a major cause of death in patients
with cancer receiving chemotherapy (Khorana et al, 2007).
Compared with patients without cancer, patients with cancer have
a three-fold elevated risk of recurrent DVT or PE, following
an initial episode of VTE. For example, in a prospective study,
Prandoni et al (2002) observed a 12-month cumulative incidence
of recurrent thromboembolism of 20.7% in 181 cancer patients,
compared with 6.8% in patients without cancer. Both groups
were managed in the same standard manner with initial heparin
followed by warfarin. Levitan et al (1999) showed that the cumu-
lative probability of re-admission to the hospital with DVT among
patients initially hospitalised for DVT and malignant disease was
approximately three-fold higher than those initially hospitalised
with DVT alone. A more recent retrospective study, conducted by
Elting et al (2004) using medical records from 529 consecutive
cancer patients, found an overall rate of recurrence of 17%,
ranging to as high as 32% in patients with inferior vena caval (IVC)
filters. Similarly, in 2006, Blom et al (2006) found that the risk of
VTE within the first 6 months after a first thrombotic event was
18.4/1000/0.5 year, with a 4.6-fold increased risk compared
with cancer patients who did not have a thrombotic event in the
6 months after cancer diagnosis. In this study, patients with
leukaemia, brain cancer, or cancer of the bladder, ureter, or testes
were at highest risk for recurrence. In the RIETE registry of 15 520
consecutive patients with VTE, cancer was present in 20% and was*Correspondence: Professor R Coleman; E-mail: R.E.Coleman@sheffield.ac.uk
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associated with a two-fold increase in the risk of fatal PE within
3 months (Laporte et al, 2008). Risk factors for the recurrence
on multivariate analysis were age o65 years or o3 months from
cancer diagnosis to VTE (Trujillo-Santos et al, 2008). Those
presenting with PE were more likely to have a PE recurrence than
those initially presenting with DVT.
The clinical picture is further complicated by the fact that
patients with cancer are also at increased risk of bleeding
during anticoagulant therapy. In the study conducted by
Prandoni et al (2002), referred to above, the 12-month cumulative
incidence of major bleeding was 12.4% in patients with cancer and
4.9% in patients without cancer – a hazard ratio of 2.2. Notably,
both recurrence and bleeding were directly related to cancer
severity, and could not be explained by over- or under-antic-
oagulation (Prandoni et al, 2002). Similarly, in the study by Elting
et al (2004), the risk of major bleeding during anticoagulant
therapy was 12% (Elting et al, 2004). In the RIETE Registry, cancer
was independently associated with a 1.7-fold increased risk of
major bleeding (Ruiz-Gime´nez et al, 2008). Risk factors for
bleeding in cancer patients were immobility, metastases, recent
bleeding, or creatinine clearance o30 ml min1 (Trujillo-Santos
et al, 2008).
A number of evidence-based guidelines on the management of
VTE in both cancer and non-cancer patients have recently been
published (Lyman et al, 2007; Kearon et al, 2008; Torbicki et al,
2008; NCCN, 2009). Given the impact of VTE on short-term and
long-term outcomes in patients with cancer – and a potential gap
between current guidelines and national clinical practice – a group
of health-care providers based in the United Kingdom gathered in
London in 2009 to discuss recent data and guidelines on cancer-
associated thrombosis and to evaluate how these recommenda-
tions can be translated into best practices for the United Kingdom.
This article, which is the third of four articles covering key
topics in cancer thrombosis, focuses on treatment and secondary
prevention of VTE in the cancer patient. The paper is structured as
a brief review of key data and guidelines on acute treatment and
secondary prevention of VTE in patients with cancer, followed
by an edited transcript of the discussion surrounding these data.
TREATMENT OF VTE IN CANCER PATIENTS
In general, the goals of VTE treatment can be summarised as
follows: (1) preventing fatal PE; (2) reducing short-term morbi-
dities associated with acute leg or lung thrombus; (3) preventing
recurrent VTE; (4) preventing the long-term sequelae of VTE
(e.g., post-thrombotic syndrome (PTS) and chronic thrombo-
embolic pulmonary hypertension).
Anticoagulant therapy is the mainstay of treatment for VTE.
Traditionally, pharmacological treatment of VTE has two phases,
with the transition between phases marked by a switch from a
parenterally administered anticoagulant with a rapid mechanism
of action (e.g., UFH, low-molecular-weight heparin (LMWH), or
fondaparinux (a synthetic pentasaccharide with the same antith-
rombin-dependent inhibition of factor Xa as LMWH)) to an oral
vitamin K antagonist (e.g., warfarin). As will be discussed, recent
clinical trials of established agents and the advent of new
pharmacological options may change this paradigm. In addition
to anticoagulants, a number of additional options exist for acute
VTE, including systemic thrombolytic therapy, catheter-directed
thrombolysis, mechanical thrombectomy, and use of vena caval
filters.
Initial treatment of VTE
The use of UFH in the initial treatment of VTE is well established.
The first and only trial that compared anticoagulant therapy
with no therapy was published in 1960 (Barritt and Jordan, 1960,
see Kearon et al, 2008). The trial that enrolled patients with
symptomatic PE (with or without symptomatic DVT), who were
randomly allocated to 1.5 days of heparin and 14 days of vitamin K
antagonist therapy or no treatment, showed that anticoagulation
significantly reduced recurrent PE and mortality. The need for
initial treatment with a rapid-acting anticoagulant such as heparin
was confirmed in a trial by Brandjes et al (1992). In this study,
patients were assigned to either combination therapy (intravenous
loading dose of 5000 U heparin, followed by an infusion of
1250 U h1 for a minimum of 7 days, in combination with vitamin
K antagonist acenocoumarol) or to acenocoumarol alone (Brandjes
et al, 1992). The study was ended early because of an excess
of events in the acenocoumarol group (20%) compared with the
combined-therapy group (6.7%). Asymptomatic extension of
venous thrombus was seen in 39.6% of patients in the aceno-
coumarol group and in 8.2% of the combination group. Notably,
the rate of major bleeding was comparable in the two groups
(Brandjes et al, 1992).
Although UFH as an initial treatment for VTE is highly effective,
it is associated with a number of important limitations, including a
short half-life, wide interpatient and intrapatient variability due to
pharmacokinetic shortcomings, the need for frequent monitoring, a
risk for heparin-induced thrombocytopenia, and, with long-term
therapy, osteoporosis (a detailed discussion of the advantages and
shortcomings of heparin can be found elsewhere in this supple-
ment). Low-molecular-weight heparins have more predictable
pharmacokinetics and greater bioavailability, which permits
body-weight-adjusted dosing without the need for laboratory
monitoring for most patients. This makes therapy much simpler
and allows for outpatient treatment of many patients, reducing
hospitalization, and improving their quality of life.
A number of clinical studies and meta-analyses have compared
the efficacy and safety of body-weight-adjusted LMWH, adminis-
tered subcutaneously without monitoring, with monitored, dose-
adjusted intravenous heparin (Quinlan et al, 2004; van Dongen
et al, 2004) and found it to be more effective, with reduced major
bleeding during initial treatment and overall mortality at follow-up
(van Dongen et al, 2004). Individual studies have not specifically
assessed the effect of LMWH as initial treatment in patients with
cancer. However, a meta-analysis of 14 trials that included cancer
subgroup data showed that LMWH was equivalent to UFH for
mortality (RR 0.89, 95% CI 0.61– 1.27) and for clinically suspected
DVT (RR 0.73, 95% CI 0.23–2.28) (Akl et al, 2008). In a post hoc
analysis that included all studies that assessed DVT (irrespective of
diagnostic strategy), LMWH was superior to UFH (RR 0.72, 95% CI
0.55– 0.94). Rates of PE and minor or major bleeding were similar
for the two strategies.
Data on the subcutaneously administered factor Xa inhibitor,
fondaparinux, in the initial treatment of VTE associated with
cancer are more limited. Post hoc analyses of the cancer patient
subgroups of two randomised trials (Bu¨ller et al, 2003, 2004) in
which fondaparinux was compared with UFH (for initial treatment
of PE) or LMWH (for initial treatment of DVT) suggest broadly
similar efficacy and safety (van Doormaal et al, 2009). However,
these data require confirmation.
In summary, LMWHs, or possibly fondaparinux, are the agents
of choice for the initial treatment of most episodes of VTE
occurring in patients with cancer. An exception is in the setting of
massive PE characterised by shock or hypotension in which UFH
remains the preferred mode of anticoagulation, as newer agents
have not been properly evaluated and an immediate anticoagulant
effect is required.
MANAGEMENT OF MASSIVE PE
Massive PE constitutes a medical emergency, and specialised
medical advice should be sought. Patients presenting with PE
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should be clinically risk stratified into high-risk and non-high-risk
groups. The former is characterised by systolic hypotension
(BPo90 mm Hg) (Torbicki et al, 2008) and carries a short-term
mortality of 415% (Torbicki et al, 2008). Pooled data from
randomised trials in non-cancer patients suggest a significant
reduction in mortality and PE recurrence with systemically
administered thrombolytic therapy in this subgroup (Wan et al,
2004). Intravenous heparin should be started immediately
(80 U kg1 as a bolus, followed by infusion at the rate of
18 U kg1 h1 and adjusted to keep the activated partial thrombo-
plastin time (aPTT) ratio between 1.5 and 2.5 times control)
(Torbicki et al, 2008). Oxygen should be administered if the
patient is hypoxic (Torbicki et al, 2008). A number of thrombolytic
regimens are approved for PE. In practice, recombinant tissue
plasminogen activator (rtPA) is commonly used at a dose of
100 mg over 2 h, or at 0.6 mg kg1 over 15 min (maximum dose
50 mg) if the patient is rapidly deteriorating (Torbicki et al, 2008).
In patients in whom thrombolytic therapy is contraindicated (e.g.,
intracranial bleeding), alternative approaches, depending on local
availability and expertise, are surgical pulmonary embolectomy
and percutaneous catheter embolectomy and fragmentation
(Torbicki et al, 2008).
Secondary prevention of VTE
Heparins are used in the initial treatment of VTE to provide
anticoagulant support during the period of time required to
achieve an appropriate international normalised ratio (INR),
generally 2.0–3.0, with oral warfarin. In patients without cancer,
warfarin is subsequently continued for a period of up to 6 months
or longer. The need for anticoagulation beyond the initial period of
heparinisation was demonstrated 30 years ago (Hull et al, 1979).
Subsequently, a large, multicentre, randomised trial suggested that
longer-duration warfarin (6 months) was superior to short-
duration therapy (6 weeks). In this study, 902 patients were
randomly assigned to receive either 6 weeks or 6 months of oral
anticoagulant therapy with a target INR of 2.0–2.85 (Schulman
et al, 1995). At 2 years, the rate of recurrence in the 6-week group
was 18.1%, compared with 9.5% in the 6-month group (see
Figure 1). There was no difference between the groups in mortality
or in the rate of major haemorrhage (Schulman et al, 1995).
Although warfarin is effective in preventing VTE recurrence, its
safe use in cancer patients is complex. Warfarin has more than 200
known drug, food, or botanical interactions that can result in
irregular responses to treatment (Bick, 2006). In cancer patients,
malnutrition, nausea, vomiting, and diarrhoea may make achiev-
ing and maintaining a therapeutic INR with an oral agent
challenging. The need for therapeutic monitoring may also present
a considerable challenge and/or an undue burden to the patient.
Interruption of therapy is more likely in patients with cancer and,
given the slow onset and offset of action of warfarin, this can lead
to considerable gaps in anticoagulant coverage (Bick, 2006). In
addition to these issues, some evidence suggests that patients with
cancer who are receiving warfarin are not only at particular risk for
recurrent thromboembolic events but also have an increased risk
for bleeding (Prandoni et al, 2002).
As a result of the shortcomings of warfarin in cancer patients,
the possible benefits of LMWH for prevention of recurrent VTE
have been evaluated in a number of randomised trials. The largest
of these was the CLOT trial in which, after initial standard LMWH
treatment, oral anticoagulation and LMWH (dalteparin) were
compared for prevention of recurrent VTE in 672 patients with
cancer (Lee et al, 2003). The recurrence rate over 6 months was 9%
in the LMWH group compared with 17% in the oral anticoagulant
group, a 52% (P¼ 0.002) reduction in favour of LMWH (Figure 2).
There were no significant differences in major bleeding or death
between the two groups (Lee et al, 2003). In this trial, dalteparin
was administered at a full-treatment dose for the first month,
followed by a 75% treatment dose for the remaining 5 months (Lee
et al, 2003). This regimen is now licensed in the United Kingdom
for treatment of VTE in patients with cancer, and a number of
systematic reviews and meta-analyses comparing LMWH with oral
anticoagulation in the long-term treatment of VTE in patients with
cancer have been published (Akl et al, 2008; Noble et al, 2008;
Louzada et al, 2009). They show that, compared with oral
anticoagulants, LMWH reduces the risk of recurrence by about
50%, with no difference between treatment modalities in major
bleeding or mortality.
The use of anticoagulation in the thrombocytopenic patient
remains challenging. Different options can be considered. For
example, the label for dalteparin recommends a reduction in daily
dose of 2500 IU if the platelet count falls to 50 –100 109/l, until it
recovers toX100 109/l, and discontinuation if the platelet count
falls to o50 109/l. In a prospective cohort study, 203 patients
with metastatic cancer and VTE received LMWH at treatment dose
for 1 week (Monreal et al, 2006). The dose was then reduced to
10 000 IU daily, irrespective of weight, for 3 months. The dose was
further reduced to 5000 IU daily at platelet countso50 109/l and
to 2500 at counts o10 109/l. Recurrent VTE developed in 9% of
patients (fatal in two patients). Five percent had a major bleed
(fatal in six patients) (Monreal et al, 2006). Although unsupported
by specific data, others have recommended a 50% dose reduction
of LMWH if the platelet count is o50 109/l and discontinuation
if the platelet count is o20 109/l (Falanga and Rickles, 2007).
Consideration should be given to insertion of a vena caval filter
if anticoagulation is contraindicated because of thrombocytopenia
or active bleeding, but again firm data are lacking. Thus, the
optimal approach to management of VTE in this setting is
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Figure 1 Cumulative probability of recurrent VTE after a first episode,
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uncertain. In individual circumstances in which there is a clear
wish not to interrupt LMWH therapy, it may be reasonable to
continue at a slightly reduced dose with platelet support to
maintain the count 450 109/l and to reduce to a prophylactic
dose, discontinue LMWH, or consider insertion of a vena caval
filter if this is not possible.
Duration of anticoagulant therapy
The optimal duration of anticoagulant therapy for prevention of
recurrent VTE in patients with cancer has not been specifically
studied. Guidelines recommend that it should continue as long as
the patient has active cancer (Lyman et al, 2007). In practice, this
means indefinite treatments in patients with metastases or in those
receiving anticancer therapy. However, each patient should be
assessed individually in terms of the risk/benefit ratio of
continuing vs stopping anticoagulants, life expectancy, quality of
life, and patient preference. The CLOT trial data referred to earlier
in favour of LMWH over oral anticoagulation did not extend
beyond 6 months. It seems likely that the benefit of LMWH would
extend beyond this period if continuing anticoagulation is
required, but consideration may be given to oral anticoagulant
therapy in individual instances.
Prevention of PTS
Post-thrombotic syndrome is a common cause of morbidity
following DVT. It occurs in 20–50% of patients overall after
symptomatic DVT. Typical features include chronic pain, swelling,
heaviness, oedema, and skin changes in the affected limb (Kahn,
2006) and can be difficult to distinguish clinically from recurrent
DVT. Use of graduated compression stockings providing an ankle
pressure of 40 mm Hg for 2 years has been compared with no
mechanical support and shown to reduce the incidence of total and
severe PTS by approximately 50% (Brandjes et al, 1997).
Vena caval filters
There is only one open-label randomised trial of IVC filters in
patients (mostly without cancer) presenting with VTE (PREPIC,
2005). In this trial, the filters were permanent and all patients
received standard anticoagulant therapy. Long-term follow-up
suggested that filter insertion was associated with a reduced risk of
PE, counter-balanced by an increased risk of DVT, and no overall
effect on mortality (PREPIC, 2005). Guidelines on the use of vena
caval filters were published by the British Committee for Standards
in Haematology (Baglin et al, 2006). The consensus was that there
were no strong evidence-based indications for filters but their
use should be considered in cases in which anticoagulation is
contraindicated, or has to be interrupted within the first month
of treatment to allow surgery, or in which there is occurrence of
PE despite adequate anticoagulation. In those cases in which anti-
coagulation is contraindicated, it should be resumed as soon as the
contraindication is no longer present, and retrievable filters should
be considered in this setting. Such filters should be retrieved
within 3 months of insertion where appropriate, or else left in
permanently.
Treatment of central venous catheter-related
thromboembolism
No randomised, controlled trials have been reported that evaluate
the effects of particular therapeutic strategies on the outcomes of
central venous catheter (CVC)-related thrombosis. Indeed, both
the natural history and management of CVC-related thrombosis
have been studied surprisingly little. In the RIETE Registry of 104
patients with cancer and CVC-related thrombosis, 10% of patients
presented with symptomatic PE and 4% developed recurrent PE at
3-month follow-up, including one fatal event (Monreal et al, 2006).
In routine practice, the catheter is commonly removed and the
patient is anticoagulated with LMWH in the standard way for VTE
in patients with cancer (i.e., with LMWH) for at least 3 months.
Whether it is necessary to remove the catheter is unclear. Current
recommendations from the National Comprehensive Cancer
Network (NCCN) are to remove the catheter if it is not required
and anticoagulate for at least 3 months. If the catheter is required
and there is no contraindication to anticoagulation, it may be
reasonable to leave the catheter in place and anticoagulate for at
least 3 months after it is eventually removed. If symptoms worsen
while the catheter remains in place or if anticoagulation is contra-
indicated, the catheter should be removed (NCCN, 2009).
Therapeutic anticoagulation failure
Therapeutic anticoagulation failure, defined as an extension of
DVT, or new DVT, or PE while on therapeutic levels of recom-
mended anticoagulation therapy, is relatively common in patients
with cancer (Prandoni et al, 2002). The recurrence rate in the
LMWH arm of the CLOT trial was 9%, much higher than would
be seen in a non-cancer population of patients with VTE. Manage-
ment in this setting has not been systematically studied, and the
measures taken in practice depend in part on the individual
circumstances in which the recurrence took place. Among patients
receiving vitamin K antagonist therapy, INR should be assessed
and adjusted, if necessary, to a higher INR range after acute
therapy with UFH or LMWH (Streiff, 2006). Alternatively, and
particularly among patients who experience recurrence despite
therapeutic levels of a vitamin K antagonist, long-term LMWH
represents a reasonable option. Vena caval filters represent
another option in patients with therapeutic anticoagulation failure,
particularly in those with VTE who have contraindications
to anticoagulant therapy (NCCN, 2009). However, the hyper-
coagulable state associated with cancer affects all vasculature;
thus, regional approaches to preventing recurrent VTE, such as
vena caval filters, may not provide adequate protection in these
patients (Streiff, 2006). In fact, placement of an IVC filter may be
associated with an increased risk for recurrent thromboembolic
disease (NCCN, 2009).
When a recurrent thrombotic event occurs in a patient receiving
heparin (UFH or LMWH), a diagnosis of heparin-induced
thrombocytopenia should be considered. Expert advice should
be sought, if necessary, for confirmation of diagnosis and
provision of non-heparin anticoagulants. More commonly, recur-
rence represents therapeutic failure. Compliance issues should be
considered along with escalation of the dose of LMWH or
converting from a once-daily to a twice-daily regimen (NCCN,
2009). For patients receiving a 75–80% maintenance dose of
LMWH, this would mean increasing to a treatment dose. For those
receiving a treatment dose at the time of recurrence, the dose could
be increased by 20–25%. This approach was reported in a recent
retrospective cohort study of 70 cancer patients with recurrent
VTE despite anticoagulation (67% while on LMWH, 33% while
receiving a vitamin K antagonist) (Carrier et al, 2009). Six (8.6%)
patients had a second recurrence with this approach. The dose was
further escalated by 20–25% in three patients who had a further
VTE event at 120% of a therapeutic dose. None of them had
a thrombotic recurrence; however, bleeding was seen in 3 out of
70 patients.
In conclusion, management of VTE in patients with cancer
remains a challenge. Recent data support the use of LMWH both
as the initial treatment for VTE and as the preferred option
for secondary prevention. It should continue for a minimum of
6 months and longer if the cancer remains active. Both recurrent
thrombosis and bleeding remain common problems, and further
studies are required to optimise management. The advent of
new anticoagulants, many of them oral, will hopefully provide
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significant advances in therapy, although the challenge of
providing anticoagulation without increasing the risk of bleeding
is likely to remain.
DISCUSSION
Annie M Young: Should we be switching people that are on
warfarin to low-molecular-weight heparin? Specifically, how
should we manage patients who have had pulmonary emboli, are
on warfarin, and have had treatment for cancer?
Peter K Maccallum: There are 2 issues. One is probably educa-
tion of clinicians. We used to get a lot of patients who would come
in under the relevant medical team and then be referred to the
anticoagulant clinic on warfarin. In my experience, a small
proportion of patients are prepared to stay on warfarin, but the
majority who are offered LMWH switch.
Annie M Young: I do not think outpatients are permitted a
choice.
Ajay K Kakkar: There are 2 reasons for that. First, dalteparin was
not available in the UK until recently for this indication. The
second issue is the point you raised. There will be a very large
number of people who, beyond 6 months, will be on warfarin,
because the general consensus view is that cancer patients with
VTE should receive anticoagulant therapy to prevent recurrent
thrombosis. Therefore, even in centres that use LMWH for the first
6 months of therapy, they put them on warfarin because they do
not want to promote self-injection. There is a study ongoing to
evaluate whether 12 months of anticoagulation with LMWH is
more effective and as safe as 6 months of treatment. Another
complicating factor is the recent availability – or imminent
availability – of newer agents. The studies for these agents will
include a small number of cancer patients, and it might be
assumed that these agents should also be used in patients with
cancer-associated thrombosis.
Faculty: Many haematologists are not aware of the issues
surrounding anticoagulation for the secondary prevention of VTE,
and they tend to keep people on warfarin. There are also many
haematologists who keep patients on LMWH, but reduce the dose
by 75% at 6 months.
Peter K Maccallum: In the absence of evidence, one can have a
discussion with the patient to make a decision. There are some
patients who are, by the end of the 6 months, unwilling to continue
daily injections.
Faculty: Another problem is the drug-drug interactions seen
with warfarin, particularly in the cancer patient who is undergoing
treatment. In many ways, LMWH is easier to use.
Faculty: Qualitative data also suggest that warfarin has a nega-
tive effect on quality of life in patients with cancer, in part because
these patients require frequent venopuncture for monitoring, but
also because of the uncertainty and lack of freedom imposed by the
monitoring regimen.
Ajay K Kakkar: Dosing presents a major issue with some
LMWHs. How do you assess the appropriate de-escalated dose to
ensure that the safety profile of the regimen is maintained? LMWH
is dosed close to the margin for an increased rate of bleeding, so it
is important to be very regimen sensitive when using these agents.
John Pasi: Separately, recurrent thrombosis occurring in fully
anticoagulated cancer patients is a major issue.
Faculty: I agree. Most of the calls I get from the oncology unit
are about patients who have had a recurrent event while on
anticoagulation. At the moment, there are no good answers, and
one has to make a common sense judgment regarding the
treatment of these patients. Another key issue is anticoagulation
in thrombocytopenic patients.
Faculty: Can we discuss duration of therapy? Many believe that
patients with advanced disease should stay on indefinite anti-
coagulation. I want to challenge that, particularly in the typical breast
or prostate cancer patient who has a median survival of 3–5 years.
Peter K Maccallum: The current recommendations suggest that
indefinite coagulation should be considered.
Faculty: But if a patient is in remission, is it safe to stop? I do
not know of any physicians who keep cancer patients on anti-
coagulation for 3–5 years after their first clot.
Annie M Young: It does happen in clinical practice.
Faculty: I would suggest that even patients with stable disease
are at higher risk of VTE than patients without cancer.
Peter K Maccallum: There is an opportunity to include this in
the consensus statement. If you look at global guidelines, the view
is generally that antithrombotic therapy should be continued while
there is active cancer or active anticancer therapy. However, there
is always a question with breast cancer – what should physicians
do with patients who are on tamoxifen for 5 years? I think this is a
very difficult question, because warfarin is associated with a major
risk for bleeding. In my opinion, warfarin at a full anticoagulant
dose in such good-prognosis patients is problematic.
Faculty: Again, there is some role for discussion with patients. In
the clinic, we often ask patients whether bleeding or having
another VTE is their biggest worry. For many of them, thrombosis
is a significant issue.
Ajay K Kakkar: This discussion clearly reflects the real problem
of where we are in terms of treatment. We have solid data to
guide treatment for the first 6 months, but no real guidance
thereafter.
CONSENSUS STATEMENT
Following the development of VTE, cancer patients remain at
elevated risk for recurrent thrombotic events. Treatment is further
complicated by the increased risk of bleeding while on anti-
coagulants.
Acute management of VTE to prevent a fatal pulmonary
embolus, as well as reduction in both short-term and long-term
Table 1 Regimens and contraindications for LMWH in the United Kingdom
Agent Brand name Regimen for secondary prevention Key contraindications/cautions in patients with cancer
Dalteparin
sodium
Fragmin For extended treatment:
K 200 IU kg1 (max 18 000 IU) s.c. once daily 1 month
K Patients with cancer undergoing regional anaesthesia
(Fragmin PI, 2009)
K Then 150 IU kg1 (max 18 000 IU) s.c. once
daily 5 months (Fragmin PI, 2009)
K Dose reduction may be warranted in patients with cancer who
experience thrombocytopenia or
have renal insufficiency (Fragmin PI, 2009)
Enoxaparin
sodium
Clexane K 1.5mg kg1 once daily for extended prophylaxis
(Meyer et al, 2002)
K Use with caution in patients with renal or hepatic impairment
and in low-weight patients (Clexane PI, 2009)
Tinzaparin Innohep K 175U kg1 once daily (Hull et al, 1979) K Use with caution in patients with renal impairment
Note that some regimens are based on studies conducted in non-cancer patients.
Treatment and secondary prevention of VTE in cancer
R Coleman and P MacCallum
S21
British Journal of Cancer (2010) 102(S1), S17 – S23& 2010 Cancer Research UK
sequelae of thrombosis, relies on the use of a rapid-acting,
parenterally administered anticoagulant such as UFH, LMWH,
or fondaparinux (see Table 1). In non-cancer patients, an oral
vitamin K antagonist (e.g., warfarin) may be initiated and
continued for at least 6 months, with indefinite treatment
considered in patients at increased risk of recurrence. In contrast,
in patients with VTE and cancer, LMWH is now the preferred
approach because of better protection against recurrent thrombo-
sis without increasing the risk of bleeding. It has additional
advantages in this population in that it is more flexible in terms
of interruption for invasive procedures or thrombocytopenia
and avoids the need for close INR monitoring that is essential
with warfarin and is particularly challenging in cancer patients.
The result is that blood tests and hospital visits can be minimised,
thereby improving the quality of life. Warfarin may still be used
in cases in which there is a clear patient preference to avoid
injections. If the cancer is in remission and there are no additional
risk factors for recurrence, anticoagulant therapy can generally
be stopped at 6 months. If the cancer remains active or there are
ongoing risk factors, consideration should be given to continuing
anticoagulation beyond 6 months, after discussing with the patient.
Randomised trials have not been conducted beyond this stage in
these patients. Low-molecular-weight heparin is likely the option
of choice in cases in which the decision is taken to continue
anticoagulation, but warfarin is an alternative approach in cases in
which this would be preferred by the patient.
Massive pulmonary embolus, catheter-related thrombosis, and
recurrent VTE despite anticoagulation are clinical scenarios for
which evidence on management in the setting of malignancy is
limited. However, guidance on treatment, based on the limited
evidence, extrapolation from a non-malignant setting, and clinical
expertise are provided. Management recommendations are based
on the NCCN Clinical Practice Guidelines in Oncology: Venous
Thromboembolic Disease (NCCN).
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CLINICAL SCENARIOS
Treatment of limb VTE
 Acute management
* Commence LMWH in preference to UFH
— Dalteparin 200 U kg1 once daily s.c.
— Tinzaparin 175 U kg1 once daily s.c.
— Enoxaparin 1.5 mg kg1 once daily s.c. (alternatively,
enoxaparin 1 mg kg1 every 12 h s.c.)
* Fondaparinux may be considered
— Fondaparinux 5 mg (o50 kg); 7.5 mg (50–100 kg); 10 mg
(4100 kg) daily s.c.
 Maintenance treatment
* Continue LMWH at 75– 80% treatment dose
* Alternatively, administer warfarin at a dose to achieve an
INR of 2 –3 if not on myelosuppressive chemotherapy or
complex supportive/concomitant medications
* Continue for at least 6 months. Indefinite treatment recom-
mended if active metastatic disease is observed or there is
continued exposure to potentially thrombogenic anticancer
therapy
 Anticoagulation contraindicated
* Recent central nervous system bleed
* Active major bleed (42 U in 24 h)
* Platelets o 50 109/l
* Severe platelet dysfunction
* Known bleeding tendency, e.g., haemophilia
* Elevated PT or aPTT above therapeutic target level
* Severely limited life expectancy or no palliative benefit
* Patient refusal
Pulmonary embolus
 Assess severity, including ECHO or CT angiography if necessary
for right heart enlargement. Consider as high risk for death
(15%) if systolic BP o90 mm Hg
 High-risk massive embolus
* Oxygen
* Commence heparin 80 U kg1 and infuse at 18 U kg1 h1 to
maintain aPTT between 2.0 and 2.5 (p 16)
* Commence thrombolyis with rtPA 100 mg over 2 h or up to
50 mg over 15 min if rapidly deteriorating
 Uncomplicated
* Treat as for VTE
CVC-related thrombosis
 Preservation of catheter access not essential
* Remove line and anticoagulate for 3 months
 Preservation of catheter access clinically important
* Anticoagulate with line in situ and for at least 3 months after
removal. Removal of line and reinsertion at a later date may
be necessary if symptoms worsen (e.g., recurrent emboli or
increasing arm swelling)
Vena caval filter placement
 Contraindications to anticoagulation (p 32)
 Failure of anticoagulation
 Non-compliance
 Documented multiple PE and chronic pulmonary hypertension
Therapeutic anticoagulant failure
 During vitamin K antagonist therapy
* Check compliance
* Increase target INR to 3– 4
* Change to LMWH
* Consider vena caval filter
 During LMWH therapy
* Check compliance
* Increase 75 to 80% maintenance dose to full-treatment dose
* Consider increase from treatment dose by 20– 25%
* Convert once-daily to twice-daily administration
* Consider vena caval filter
Treatment and secondary prevention of VTE in cancer
R Coleman and P MacCallum
S23
British Journal of Cancer (2010) 102(S1), S17 – S23& 2010 Cancer Research UK
